This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-β1a in relapsing—remitting multiple sclerosis (RRMS). Patients (n = 180) were randomized (2 : 1) to IFN-β1a or placebo for 16 weeks; all patients then received IFN-β1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-β1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-β1a by week 4 (post hoc analysis; p = 0.015). The new formulation of sc IFN-β1a has rapid beneficial effects on MRI outcomes in RRMS.
Giovannoni G. , Barbarash O., Casset-Semanaz F., et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif® New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler2009; 15: 219-228.
2.
McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121-127.
3.
Kurtzke JFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444-1452.
4.
Rovaris M., Inglese M., van Schijndel RA, et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol2000; 247: 960-965.
5.
Li DK, Paty DW, UBC MS MRI Analysis Research Group, /PRISMS Study Group.Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol1999; 46: 197-206.
6.
Sormani MP, Bruzzi P., Miller DH, Gasperini C., Barkhof F., Filippi M.Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci1999; 163: 74-80.
7.
Zhao Y., Traboulsee A., Petkau AJ, Li D.Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurol2008; 70: 1092-1097.
